{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:03:41Z","timestamp":1768619021600,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F30CA203238"],"award-info":[{"award-number":["F30CA203238"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM007739"],"award-info":[{"award-number":["T32GM007739"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Mycology Case Reports"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.mmcr.2021.03.004","type":"journal-article","created":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T01:41:14Z","timestamp":1615686074000},"page":"43-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12\/23 therapy"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3431-2163","authenticated-orcid":false,"given":"Yun-Han","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1846-7114","authenticated-orcid":false,"given":"Reed","family":"Magleby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2462-0004","authenticated-orcid":false,"given":"Rema","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harjot K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mmcr.2021.03.004_bib1","doi-asserted-by":"crossref","unstructured":"Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor \u03b1 for crohn's disease. N. Engl. J. Med.. 1997. Oct. 9;337(15):1029\u20131036.","DOI":"10.1056\/NEJM199710093371502"},{"key":"10.1016\/j.mmcr.2021.03.004_bib2","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Gasink C, Gao L-L, Blank MA, Johanns J, Guzzo C, et al Ustekinumab induction and maintenance therapy in refractory crohn's disease. N. Engl. J. Med.. 2012. Oct. 18;367(16):1519\u20131528.","DOI":"10.1056\/NEJMoa1203572"},{"issue":"1","key":"10.1016\/j.mmcr.2021.03.004_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of serious infections with biologic and\/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.mmcr.2021.03.004_bib4","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","article-title":"Ustekinumab safety in psoriasis, psoriatic arthritis, and crohn's disease: an integrated analysis of phase II\/III clinical development programs","volume":"42","author":"Ghosh","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.mmcr.2021.03.004_bib5","doi-asserted-by":"crossref","unstructured":"Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, et al IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of crohn's disease. J Crohns Colitis. 2020. Jan. 1;14(1):23\u201332.","DOI":"10.1093\/ecco-jcc\/jjz110"},{"key":"10.1016\/j.mmcr.2021.03.004_bib6","unstructured":"Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, et al Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J. Drugs Dermatol. JDD. 2015. Jul;14(7):706\u2013714."},{"issue":"1","key":"10.1016\/j.mmcr.2021.03.004_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.14794","article-title":"Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy","volume":"48","author":"Sandborn","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"10155","key":"10.1016\/j.mmcr.2021.03.004_bib8","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","article-title":"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomized, controlled study","volume":"392","author":"van Vollenhoven","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.mmcr.2021.03.004_bib9","doi-asserted-by":"crossref","unstructured":"Shim HH, Ma C, Kotze PG, Seow CH, Al-Farhan H, Al-Darmaki AK, et al Preoperative ustekinumab treatment is not associated with increased postoperative complications in crohn's disease: a Canadian multi-centre observational cohort study. J Can Assoc Gastroenterol. 2018. Sep;1(3):115\u2013123.","DOI":"10.1093\/jcag\/gwy013"},{"key":"10.1016\/j.mmcr.2021.03.004_bib10","doi-asserted-by":"crossref","unstructured":"Highland MA, Chaturvedi S, Perez M, Steinberg H, Wallace R. Histologic and molecular identification of disseminated Histoplasma capsulatum in a captive brown bear (Ursus arctos). J. Vet. Diagn. Invest.. 2011. Jul. 1;23(4):764\u2013769.","DOI":"10.1177\/1040638711406976"},{"key":"10.1016\/j.mmcr.2021.03.004_bib11","doi-asserted-by":"crossref","unstructured":"Benedict K, Beer KD, Jackson BR. Histoplasmosis-related healthcare use, diagnosis, and treatment in a commercially insured population, United States. Clin. Infect. Dis.. 2020. Mar. 3;70(6):1003\u20131010.","DOI":"10.1093\/cid\/ciz324"},{"key":"10.1016\/j.mmcr.2021.03.004_bib12","author":"Benedict"},{"issue":"4","key":"10.1016\/j.mmcr.2021.03.004_bib13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1439-0507.2006.01253.x","article-title":"Histoplasmosis: a review for clinicians from non-endemic areas","volume":"49","author":"Wheat","year":"2006","journal-title":"Mycoses"},{"key":"10.1016\/j.mmcr.2021.03.004_bib14","doi-asserted-by":"crossref","unstructured":"Ibrahim A, Ahmed M, Conway R, Carey JJ. Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis. J. Clin. Med.. 2019. Jan;8(1):15.","DOI":"10.3390\/jcm8010015"},{"key":"10.1016\/j.mmcr.2021.03.004_bib15","doi-asserted-by":"crossref","unstructured":"Zhou P, Sieve MC, Tewari RP, Seder RA. Interleukin-12 modulates the protective immune response in SCID mice infected with Histoplasma capsulatum. Infect. Immun.. 1997. Mar;65(3):936\u2013942.","DOI":"10.1128\/iai.65.3.936-942.1997"},{"key":"10.1016\/j.mmcr.2021.03.004_bib16","doi-asserted-by":"crossref","unstructured":"Kroetz DN, Deepe GS. The role of cytokines and chemokines in Histoplasma capsulatum infection. Cytokine. 2012. Apr;58(1):112\u2013117.","DOI":"10.1016\/j.cyto.2011.07.430"},{"issue":"4","key":"10.1016\/j.mmcr.2021.03.004_bib17","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mmcr.2021.03.004_bib18","doi-asserted-by":"crossref","unstructured":"Hage CA, Ribes JA, Wengenack NL, Baddour LM, Assi M, McKinsey DS, et al A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin. Infect. Dis.. 2011. Sep. 1;53(5):448\u2013454.","DOI":"10.1093\/cid\/cir435"}],"container-title":["Medical Mycology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211753921000130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211753921000130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T18:02:50Z","timestamp":1761933770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211753921000130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":18,"alternative-id":["S2211753921000130"],"URL":"https:\/\/doi.org\/10.1016\/j.mmcr.2021.03.004","relation":{},"ISSN":["2211-7539"],"issn-type":[{"value":"2211-7539","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12\/23 therapy","name":"articletitle","label":"Article Title"},{"value":"Medical Mycology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mmcr.2021.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology.","name":"copyright","label":"Copyright"}]}}